|
 |
Noms commerciaux |
|
|
Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires
|
|
Abbocurium |
Pologne |
|
Acurmil |
Italie |
|
Ancour |
Iran |
|
Anecur |
Iran |
|
Atacur |
Arabie Saoudite |
|
Atacurin |
Iran |
|
Atrabesylate |
Egypte |
|
Atracur |
Equateur |
|
Atracurio |
Argentine, Brésil, Espagne |
|
Atracurio besilato |
Chili, Italie, Pérou, Vénézuela |
|
Atracurium |
Allemagne, Arabie Saoudite, Argentine, Autriche, Egypte, Emirats Arabes Unis , Grande Bretagne, Iran, Italie, Malaisie, Suède |
|
Atracurium besilat |
Autriche |
|
Atracurium besilate |
Arabie Saoudite, Australie, Canada, Egypte, Emirats Arabes Unis , Etats Unis d’Amérique, Iran, Nouvelle Zélande |
|
Atralex |
Malaisie |
|
Atrasyl |
Turquie |
|
Besilato Atracurio |
Chili, Espagne, Portugal |
|
Besitrac |
Brésil |
|
Faulcurium |
Egypte, Portugal |
|
Gelolagar |
Argentine |
|
Laurak |
Espagne |
|
Neucurium |
Turquie |
|
Notrixum |
Turquie |
|
Relactrac |
Colombie |
|
Relatrac |
Mexique |
|
Tracrium |
Allemagne, Arabie Saoudite, Argentine, Australie, Autriche, Belgique, Chili, Colombie, Egypte, Emirats Arabes Unis , Equateur, Espagne, Etats Unis d’Amérique, France, Grande Bretagne, Grèce, Hongrie, Iran, Italie, Luxembourg, Malaisie, Maroc, Mexique, Nouvelle Zélande, Pays bas, Pologne, Portugal, Roumanie, Suède, Suisse, Tunisie |
|
Tracumek |
Pérou |
|
Tracurix |
Argentine |
|
Tracuron |
Argentine |
|
|
 |
 |
Bibliographie : Atracurium besylate |
|
|
Type |
Source |
| 285 |
Revue |
Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Clin Ther 1996 ; 18: 246-255. |
| 300 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 319 |
Revue |
Hadzija BW, Lubarsky DA.
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Am J Health-Syst Pharm 1995 ; 52: 997-999. |
| 402 |
Revue |
Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821. |
| 657 |
Revue |
Pramar YV, Loucas VA, Word D.
Chemical stability and adsorption of atracurium besylate injections in disposable plastic syringes.
J Clin Pharm Ther 1996 ; 21: 173-175. |
| 660 |
Revue |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 813 |
Revue |
Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68. |
| 865 |
Revue |
Bhatt-Mehta V, Hirata S.
Physical compatibility and chemical stability of atracurium besylate and midazolam hydrochloride during intravenous coinfusion.
Int J Pharm Compound 1998 ; 2: 79-81. |
| 939 |
Revue |
Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 1093 |
Revue |
Fisher DM, Canfell, Miller RD.
Stability of atracurium administered by infusion.
Anesthesiology 1984 ; 61: 347-348. |
| 1611 |
Revue |
Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506. |
| 1647 |
Revue |
Ackland G.
Physical incompatibility between atracurium and intravenous diclofenac.
Anaesthesia 2001 ; 56: 294. |
| 1721 |
Revue |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1803 |
Revue |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 3373 |
Revue |
Khan S, Stannard N, Greijn J.
Precipitation of thiopental with muscle relaxants: a potential hazard.
J R Soc Med Sh Rep 2011 ; 2: 58. |
| 3502 |
Laboratoire |
Propofol (Diprivan®) - Summary of Products Characteristics
Astra Zeneca 2012 |
| 3629 |
Laboratoire |
Atracurium (Atracurium solution for injection/infusion®) - Summary of Product Characteristics
Actavis UK 2014 |
| 3659 |
Laboratoire |
Propofol (Diprivan®) - Résumé des caractéristiques du produit
AstraZeneca 2016 |
| 3676 |
Laboratoire |
Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit
Hospira 2014 |
| 4428 |
Revue |
Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132. |
|
|
